BioSpace News Archive

Sexton Biotechnologies has announced a new solution for biotech manufacturing companies looking for flexible automation options.

Junshi Biosciences (HKEK: 1877), a China-based biopharmaceutical company specializing in discovery, development and commercialization of novel therapies, and Merck, a world leading science and technology company, today announced their collaboration on a clinical trial program designed to investigate the efficacy and safety of anti-PD-1 mAb toripalimab

The American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research outlined their guidelines and measures for combating the spread of COVID-19, while providing protection to transplant patients.

Spark Therapeutics, a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the publication of new research in the journal Nature Medicine demonstrating that treatment with immunoglobulin G-degrading (IgG) enzyme of Streptococcus pyogenes

Meditech Spine has received FDA 510(k) clearance to market the CURE™ Opel-L (S) system, a new lumbar plate option which expands upon the previously cleared CURE™ LP Plate System and compliments its Talos®-A (HA) Interbody system

The Medical Device Innovation Consortium (MDIC) today announced that Flora Sandra Siami, MPH, has joined the organization as Senior Vice President for the National Evaluation System for health Technology Coordinating Center (NESTcc).

Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the results from the one-year follow-up study to their Phase 2 open label, multicenter pilot study of Cryopreserved Umbilical Cord allograft TTAX01.

TraceLink Inc., the leading digital platform company for the life science supply chain, announced it has earned ISO 9001:2015 certification, a globally recognized quality management standard.

PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is issuing this press release in response to a request by the Investment Industry Regulatory Organization of Canada to comment on recent trading activity of its common shares.

Today, Change Healthcare (Nasdaq: CHNG) announced the acquisition of PDX, a leader in providing patient centric and innovative technologies for pharmacies and health systems.